BIOLOGICAL · Unmapped registry intervention
ABO2109 and toripalimab
Find medicine records ·
Find other trials using this name
Clinical trial
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
NCT07683832
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedSafety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: EARLY_PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non-Small Cell Lung Cancer NSCLCunresolved
Interventions
ABO2109 and toripalimabBIOLOGICAL
Sponsors & collaborators
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07683832 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.